Emergent BioSolutions gains rights to distribute KLOXXADO® Nasal Spray for opioid overdose treatment.

From GlobeNewswire: 2025-01-14 07:30:34

Emergent BioSolutions Inc. has acquired exclusive commercial rights to Hikma Pharmaceuticals’ KLOXXADO® Nasal Spray, an 8 mg naloxone agent for opioid overdose treatment. This complements their existing NARCAN® Nasal Spray, with a recent CDC report showing a decrease in opioid overdose deaths, signaling progress in the fight against the epidemic. The two nasal sprays will be distributed through various channels to increase access and awareness. KLOXXADO® will be integrated into Emergent’s distribution network for bulk purchases by qualified organizations. Both products are crucial in reversing opioid overdose effects and saving lives. Emergent BioSolutions is expanding its distribution of NARCAN® Nasal Spray 4 mg and prescription KLOXXADO® Nasal Spray 8 mg to address opioid overdose emergencies. Symptoms of overdose include seizures, increased reflexes, and crying more than usual. Users should disclose medical conditions, medications, and pregnancy status to their doctor before using KLOXXADO®. Possible side effects include opioid withdrawal symptoms and aggressive behavior post-reversal. KLOXXADO® is safe and effective for infants and children in overdose situations. Proper dosage and administration instructions are provided, and storage guidelines must be followed. For more information, visit the website provided. Emergent Devices will now distribute KLOXXADO® Nasal Spray, in addition to NARCAN® Nasal Spray, to combat opioid overdoses. The focus is on increasing access and awareness, meeting the demand for lifesaving naloxone nasal spray. Centers for Disease Control and Prevention data shows the ongoing need for these emergency treatments in communities across the country.



Read more at GlobeNewswire: Emergent BioSolutions Gains Exclusive Commercial Rights to